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Real-World Therapies and the Problem of Vivax Malaria
J. Kevin Baird, Ph.D.
Wellems and Miller1 wrote of two worlds of ma-
laria: one, of the residents of rural tropical areas 
in which the disease is endemic, and the other, 
of travelers to those areas, who typically have 
greater resources. The distinction is sharp, valid, 
and important in considering the development 
of tools to combat the global burden of malaria. 
Drugs considered safe and effective in one world 
may not be so in the other.2 The majority of the 
hundreds of millions of people in whom malaria 
will develop over the next year will obtain and 
consume antimalarial medication without medical 
supervision. Although the licensing of complex 
or poorly tolerated therapeutic regimens requir-
ing clinical screening for contraindications may 
be perfectly suitable for populations with access 
to close clinical supervision, distributing the 
same regimen in the rural tropics is reckless.
Two other worlds of malaria are those with 
and without endemic Plasmodium vivax. Vivax ma-
laria was known as “benign tertian malaria” for 
more than a century and is still viewed as rarely 
dangerous; evidence suggests a historical under-
estimation of both the burden of disease and the 
potential for death with P. vivax infection.3-7 En-
demic vivax malaria occurs throughout the trop-
ics, except where there is a natural absence of 
anopheline mosquitoes (east of Vanuatu in the 
South Pacific) or among populations lacking the 
Duffy receptor on red cells (in much of Africa). 
Vivax malaria stands alone among the plasmo-
dia infecting humans in its capacity to reach well 
into the temperate latitudes, as it does today — 
up to the Korean peninsula and across the south-
ern temperate latitudes of Asia to the Mediterra-
nean Sea. Approximately 2.6 billion people are at 
risk, and estimates of annual infections range 
from 70 to 390 million,3,4 with about 80% occur-
ring in South and Southeast Asia. Vivax malaria 
accounts for at least 70% of the malaria burden 
in the Americas.
Objective examination of the clinical evidence 
underpinning available therapies for P. vivax in-
fection reveals a conspicuous neglect of this para-
site.5 More importantly, the analytical tools for 
critically assessing experimental or standard ther-
apies may be considered insufficient, at best, for 
the task of identifying the treatments that are 
safe and effective and capable of reducing the 
disease burden of vivax malaria.
The distinction between the worlds of ma-
laria with and without P. vivax finds expression 
in the study by Karunajeewa et al.8 (Australian 
New Zealand Clinical Trials Registry number, 
ACTRN12605000550606) reported in this issue 
of the Journal. This state-of-the-art clinical trial 
evaluates the safety, tolerability, and efficacy of 
therapeutic options among young children ex-
posed to endemic falciparum and vivax malaria 
in Papua New Guinea. By virtue of the analytical 
tools applied, the findings with regard to P. falci-
parum provide useful insights. The estimated 88% 
efficacy of dihydroartemisinin–piperaquine falls 
well below other estimates of efficacy for this 
combination against this parasite. The authors 
point to both suboptimal absorption of piper-
aquine and to cross-resistance between chloro-
quine and piperaquine by local parasites in vitro 
as a possible basis for the relatively poor perfor-
mance of the drug combination. Their carefully 
assembled evidence makes a compelling case for 
the selection of artemether–lumefantrine for 
treatment of uncomplicated falciparum malaria 
in northwestern Papua New Guinea.
The authors have much less analytical leverage 
with regard to the data on P. vivax, however. The 
liver stage of P. vivax responsible for relapse (the 
hypnozoite) casts a nearly opaque shadow of 
ambiguity across the data. The curve showing 
occurrences of recrudescent infection provides 
almost no useful information for discerning the 
advantage of one therapeutic option over another: 
 Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Baird in the New England Journal of Medicine (2008) 359). 
Copyright 2008, Massachusetts Medical Society. Used by permission.
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 359;24 www.nejm.org december 11, 20082602
all appear highly effective in the week after 
treatment and uniformly poor thereafter. Dihydro-
artemisinin–piperaquine appears to be the least 
inadequate of the four, but this may be an illusion 
created by successfully suppressed relapse. The 
authors did not correct the data for post-therapy 
reinfection or relapse using a polymerase-chain-
reaction (PCR) assay, because no existing assay 
can achieve such a correction. Nor did they ex-
amine parasite responses to these drugs in vitro, 
because no standardized protocol for doing so 
exists, and experimental protocols yield findings 
that are notoriously difficult to interpret.9,10 The 
authors cannot assign an attributable risk of re-
infection as compared with relapse among their 
subjects, because there are no baseline data for 
doing so. Even if the authors had applied pri-
maquine against hypnozoites, the only drug cur-
rently approved and available for this use, they 
could not have assumed its good efficacy, because 
there are no data to support that contention.
The data presented by Karunajeewa et al. 
should nonetheless alert public health and health 
care providers alike to the substantial health bur-
den imposed by hypnozoites. One third of the 
children with P. falciparum infection in this study 
had recurrent P. falciparum parasitemia within 42 
days after the start of treatment. Almost two 
thirds of those cases proved to be reinfections, 
suggesting a 6-week cumulative incidence of new 
infections of about 20%. Incidence-density stud-
ies in nearby Western New Guinea consistently 
found new P. falciparum infections to outnumber 
new P. vivax infections by about 2:1.11,12 The 
6-week cumulative incidence of new P. vivax in-
fections in the study by Karunajeewa et al. may be 
thus crudely estimated at less than 10%, where-
as the realized cumulative incidence of recurrent 
P. vivax parasitemia was about 65%. During the 
follow-up period, P. vivax parasitemia developed 
in almost half of the subjects treated for acute 
falciparum malaria. The hypnozoite appears to 
be the overwhelmingly dominant source of new 
parasitemia and the consequent opportunities for 
disease and further transmission.
For operational malarial control, attacking the 
hypnozoite may be more effective in relieving 
disease burdens than measures minimizing hu-
man contact with anopheline mosquitoes. What 
can be said of primaquine, the only drug avail-
able for eliminating this source of vivax malaria? 
Primaquine has been in continuous use for more 
than 50 years. Standard therapy is implemented 
over 14 days. Good tolerability requires that a 
snack or meal be taken with the drug. Safe ad-
ministration requires that pregnancy and glucose-
6-phosphate dehydrogenase deficiency are ruled 
out, by means of clinical and laboratory screen-
ing. Mechanisms of the drug’s toxicity and activity 
are not known. There is no standardized means 
of gauging its efficacy against hypnozoites. No 
body of current clinical data show that it has 
good efficacy in the field, and it may have no ef-
ficacy against hypnozoites unless administered 
with an appropriate companion drug.13-15
The inadequacy of primaquine and its critical 
importance in attacking vivax malaria symbolizes 
the technical poverty of the malaria world that 
includes P. vivax. If we are to remove the barriers 
separating the two worlds of malaria identified 
by Wellems and Miller, we must deal with the 
control of vivax malaria, and perhaps its eradica-
tion. It seems likely that this will prove unman-
ageable without a safe, practical, and effective 
therapy aimed at the hypnozoite.
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